Crispr Therapeutics shares tumble after significant earnings miss

Investing.com -- CRISPR Therapeutics (NASDAQ:CRSP) reported a wider-than-expected loss for the second quarter of 2025, sending shares down 6.1% as both earnings and revenue fell significantly short of analyst expectations.

The gene-editing company posted a second quarter loss of $2.40 per share, substantially worse than the analyst estimate of $1.40 per share. Revenue came in at just $890,000, far below the consensus estimate of $5.81 million. The disappointing results were primarily driven by higher-than-expected acquired in-process R&D expenses of $96.3 million related to the company’s recent agreement with Sirius Therapeutics.

Despite the financial miss, CRISPR Therapeutics highlighted progress in its commercial rollout of CASGEVY, its gene therapy for sickle cell disease and transfusion-dependent beta thalassemia. The company has activated 75 authorized treatment centers globally, with approximately 115 patients completing their first cell collection and 29 patients receiving infusions through June 30.

"We are entering the second half of the year with momentum across both our commercial and clinical programs," said Samarth Kulkarni, Ph.D., Chairman and CEO of CRISPR Therapeutics. "The activation of 75 authorized treatment centers for CASGEVY has been achieved, marking a meaningful step in expanding patient access, while clinical trials across multiple other programs continue to advance."

The company’s cash position stood at $1.72 billion as of June 30, 2025, down from $1.90 billion at the end of 2024. R&D expenses decreased to $69.9 million from $80.2 million YoY, while general and administrative expenses slightly decreased to $18.9 million from $19.5 million in the same period last year.

CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas, including its in vivo liver editing programs CTX310 and CTX320, as well as next-generation allogeneic CAR T product candidates CTX112 and CTX131. The company expects to present complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.